Indofil Industries: The Agrochemical Giant Hiding at 6.5x P/E

India's chemical industry is projected to reach USD 255 billion by 2030, growing at 8-9% a year (Source: Kotak Neo). Within it, the agrochemical market is expected to grow at about 7% annually over 2026-2031 (Source: Mordor Intelligence). Rising food demand, expanding exports and incentives for precision farming, which should lift demand for drone-compatible formulations, are the main drivers. Geopolitical disruptions, weather volatility, input cost inflation and tighter export-market regulation are the key headwinds.

Indofil Industries, incorporated in 1962 as a subsidiary of Rohm & Haas, sits inside this landscape. It is now a KK Modi Group company with three divisions: agrochemicals, specialty performance chemicals (Indofil Innovative Solutions) and plant nutrition (IndoLife). It is fully integrated, manufactures in Thane and Dahej, and exports to over 128 countries with more than 586 active international product registrations. Mancozeb, a broad-spectrum fungicide, remains its flagship product.

Source: Annual Reports

The financial turnaround is striking. Revenue from operations rose from ₹2,795 crore in FY22 to ₹3,586 crore in FY26. Over the same period, EBITDA more than doubled to ₹991 crore, and PAT nearly tripled to ₹612 crore. PAT margin expanded from 7.8% to 17.1%. The balance sheet is almost clean, with debt-equity falling from 0.31 to 0.01. Returns are less dramatic. ROE has stayed between 8.6% and 9.6% because equity has grown alongside earnings, though ROCE improved to 13.64% in FY26.

Against peers, Indofil is the smallest of the three companies compared but the fastest growing, with a three-year revenue CAGR of 5.7%. It has the highest EBITDA margin in the group. Its 17.1% PAT margin sits between PI Industries at 19.7% and UPL at 4.3%. Yet it trades at a P/E of just 6.5x, against 23.1x for UPL and 31.1x for PI Industries. That is a discount of roughly 72% and 79%.Some discount is justified. Indofil is unlisted, illiquid and promoter-led, and crop protection is cyclical. 

To reflect this, we used a scenario-based forward P/E model through FY30E. Revenue growth of 8%, 9% and 10% is anchored to industry estimates. We assume a normalised PAT margin of 15%, below FY26's peak, and P/E multiples of 12x, 15x and 20x. This gives a value per share of ₹3,880 to ₹6,960, against a current price of ₹1,750, implying returns of 121% to 297% over four years.

Most of that return comes from re-rating rather than earnings growth, and the valuation is equally sensitive to the multiple and the margin. The main risks are a persistent discount if the stock stays illiquid, a reversal of FY26's margin gains and slower industry growth. A listing or better liquidity could narrow the gap, but there is no certainty it will.